^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IGF2BP1 overexpression

    i
    Other names: Insulin Like Growth Factor 2 MRNA Binding Protein 1, IMP-1, Insulin-Like Growth Factor 2 MRNA-Binding Protein 1, Coding Region Determinant-Binding Protein, IGF-II MRNA-Binding Protein 1, IGF2 MRNA-Binding Protein 1, Zipcode-Binding Protein 1, VICKZ Family Member 1, CRD-BP, VICKZ1, CRDBP, ZBP-1, IMP1, ZBP1, Insulin-Like Growth Factor 2 MRNA Binding Protein 1 DeltaN CRDBP, Insulin-Like Growth Factor 2 MRNA Binding Protein 1, IGF II MRNA Binding Protein 1, IGF2BP1
    Entrez ID:
    10642
    1year
    IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. (PubMed, Genes Dis)
    Therefore, IGF2BP1 acts as a post-transcriptional enhancer of CDC5L in an m6A-dependent manner to promote the proliferation of MM cells with 1q+. Our work identified a novel IGF2BP1-CDC5L axis and provided new insight into developing targeted therapeutics for MM patients with 1q+.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1)
    |
    IGF2BP1 overexpression
    over1year
    Exosomal lncRNA ROR1-AS1 from cancer-associated fibroblasts inhibits ferroptosis of lung cancer cells through the IGF2BP1/SLC7A11 signal axis. (PubMed, Cell Signal)
    CAFs secrete exosomal ROR1-AS1 to promote the expression of SLC7A11 by interacting with IGF2BP1, thereby inhibiting ferroptosis of lung cancer cells.
    Journal
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    ROR1 expression • IGF2 overexpression • IGF2BP1 overexpression • SLC7A11 expression • ROR1 overexpression
    |
    erastin
    almost2years
    Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling. (PubMed, Am J Cancer Res)
    Meanwhile, we discovered that ANLN can stabilize the proto-oncogene c-Myc and activate the MAPK signaling pathway through IGF2BP1. These findings indicate that ANLN could be a potential therapeutic target in PCa.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ANLN (Anillin Actin Binding Protein)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    almost2years
    IGF2BP1 facilitates non-small cell lung cancer progression by regulating the KIF2A-mediated Wnt/β-catenin pathway. (PubMed, Funct Integr Genomics)
    KIF2A exerted the same functions as IGF2BP1 via the Wnt/β-catenin signaling. In conclusion, IGF2BP1 enhances NSCLC malignant progression by stabilizing KIF2A to modulate the Wnt/β-catenin pathway.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression
    almost2years
    BIRC5 facilitates cisplatin-chemoresistance in a m A-dependent manner in ovarian cancer. (PubMed, Cancer Med)
    The regulation of its expression and the stability of its mRNA were influenced by m A modifications involving both METTL3 and IGF2BP1. These insights presented BIRC5 as a promising potential therapeutic target for addressing cisplatin resistance in OC.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • METTL3 (Methyltransferase Like 3)
    |
    BIRC5 expression • IGF2 overexpression • IGF2BP1 overexpression
    |
    cisplatin
    2years
    N-Methyladenosine (mA) Reader IGF2BP1 Accelerates Gastric Cancer Development and Immune Escape by Targeting PD-L1. (PubMed, Mol Biotechnol)
    Moreover, the IGF2BP1 overexpression enhanced the stability of PD-L1 mRNA, thereby deteriorating the immune escape of gastric cancer cells. Collectively, these results describe a novel regulatory mechanism of IGF2BP1 by regulating PD-L1 through mA epigenetic modification, which might provide insights for gastric cancer immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    PD-L1 overexpression • IGF2BP1 overexpression
    over2years
    RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia. (PubMed, J Exp Clin Cancer Res)
    Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2 overexpression • IGF2BP1 overexpression • RUNX1 overexpression
    over2years
    Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. (PubMed, Exp Hematol Oncol)
    Elevated expression of IGF2BP1 is a frequent event in ESCC tissues and might be a candidate biomarker for the disease. IGF2BP1 overexpression promotes the invasion and migration of ESCC cells by activating the INHBA-Smad2/3 pathway, providing a potential therapeutic target for ESCC patients with high expression of IGF2BP1.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • G3BP1 (G3BP Stress Granule Assembly Factor 1)
    |
    IGF2 elevation • IGF2BP1 overexpression
    almost3years
    IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. (PubMed, Cancer Lett)
    More importantly, BTYNB, a recently identified IGF2BP1 inhibitor, exerted promising anti-tumor efficacy in a patient-derived xenograft (PDX) model, and IGF2BP1 conditional knockout (cKO) reduced the tumor burden. These results demonstrate the crucial role of IGF2BP1 in iCCA progression via mA-dependent modification, highlighting IGF2BP1 as a potential therapeutic target in iCCA.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF2 (Insulin-like growth factor 2) • MMP2 (Matrix metallopeptidase 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    |
    IGF2BP1 overexpression
    almost3years
    LINC00858 facilitates formation of hepatic metastases from colorectal cancer via regulating the miR-132-3p/IGF2BP1 axis. (PubMed, Biol Chem)
    LINC00858 could facilitate CRC tumor growth and hepatic metastases. LINC00858 induced CRC hepatic metastases via regulating miR-132-3p/ IGF2BP1, and this study may deliver a new diagnostic marker for the disease.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • MIR132 (MicroRNA 132)
    |
    IGF2 overexpression • IGF2BP1 overexpression